113 results about "Microvesicle" patented technology

Disclosed is a method for the treatment and / or diagnosis of cancer, using bacterial cell-derived microvesicles, which is highly effective in cancer therapy with a significant reduction in side effects. Also, a method is provided for delivering of a drug therapeutic or diagnostic for a disease, using bacterial cell-derived microvesicles loaded with the drug, thereby treating and diagnosing the disease effectively and specifically.

The present invention relates to a microvesicle that is derived from nucleated mammalian cells, which are smaller than the nucleated cells. The microvesicles of the present invention can be used in the delivery of a therapeutic or diagnostic substance to specific tissues or cells, and more particularly, relates to microvesicles derived from monocytes, macrophages, dendritic cells, stem cells or the like, which can be used to deliver specific therapeutic or diagnostic substances for treating and / or diagnosing tissue associated with cancer, diseased blood vessels, inflammation, or the like.

The invention discloses a foaming agent and circulative micro-foam drilling fluid as well as well-drilling technological method; wherein, the foaming agent comprises 30% neopelex ABS, and 70% lauryl sodium sulfate SDS; the circulative micro-foam drilling fluid is produced through adding 0.1% sodium hydroxide, 0.2 to 0.3% xanthan gum XC, 0.2 to 0.3% medium viscosity flocculent cellulose CMC and 0.1 to 0.3% foaming agent; during well drilling construction, the circulative micro-foam drilling fluid is first to be prepared, and then is used to perform the wet drilling. With the foaming agent added to the circulative micro-foam drilling fluid, the formed micro-foam slurry has the advantages of good leakage proof and plugging effect, great lubrication performance, good rheology, obvious improved drilling quality and drilling efficiency.

The invention relates to a formulation comprising a dry material (e.g. lyophilised or spray dried) comprising at least one film forming surfactant and a gas or a gas mixture usable in diagnostic imaging, to a process for the preparation thereof and to a suspension obtainable by reconstituting said formulation with an aqueous carrier for use in contrast imaging. The invention also relates to a container comprising the dry material in contact with a gas. The gas associated with the dry material is at a pressure lower than the atmospheric pressure.

The present invention relates to direct protein delivery with engineered micro vesicles.

The invention relates to a polyamine micromolecular compound, comprising the following structures described in the specification, wherein M<x+> is 0, Zn<2+>, Ga<3+>, Gd<3+>, Ca<2+> or other divalent metal ions and trivalent metal ions; S is a reporter group (including a nuclide labeling prothetic group, a paramagnet, a fluorescein or a microvesicle), such as the nuclide labeling prothetic group: -<11>CH3, -CH2CH2<18>F, -CH2CH2(OCH2CH2)2NHCOC6H4<18>F-p or -CH2CH2(OCH2CH2)2NH-CH2CH2<18>F; R is -H, -OCH3, -OCH2CH3 or -Cl; and R1, R2, R3 and R4 are hydrogen, carboxyl, alkane, alkylene or heteroalkyl. The invention further relates to application of the compound in preparing cell death or apoptosis developers of target phosphatidyl serine (PS) and / or apoptotic cell early free Zn<2+>. The compound provided by the invention is a specific multiamine micromolecular developer for target phosphatidyl serine (PS) and / or apoptotic cell early free Zn<2+>, which can be used for monitoring curative effects of PS-related anti-tumor chemotherapy, radiotherapy, biological therapy and the like; the compound can be used for early differential diagnosis of neurodegenerative diseases (senile dementia and Parkinson's disease), cerebral apoplexy, AIDS (Acquired immune deficiency syndrome), thrombus, atheromatous plaque and myocardial infarction; and the compound can also be used for differential diagnosis and curative effect monitoring of other diseases related to PS expression in the cell death or apoptosis process, such as inflammation development and anti-inflammation therapeutic development.

A system based on envelope microvesicle for perfusion imaging and ultrasonic controlled release is composed of ultrasonic imaging probe, fully digitalized ultrasonography B, RF data output port, high-speed data acquisition card, PC as main controller, any waveform generator, 3D moving unit, moving controller and single-cell transducer. On the basis of fully digitalized ultrasonography B, a blood perfusion imaging algorithm is used for making a decision to obtained original RF data and performing real-time imaging. Under the guide of perfusion image, the release of envelope microvesicles is controlled.

The invention discloses a photoacoustic microscope. The photoacoustic microscope comprises a microscope system, a signal collection control system and a driving system. The invention further discloses a method for monitoring breaking of microvesicles in biological tissue with the use of the photoacoustic microscope. The photoacoustic imaging is combined with features of high contrast ratio of optical imaging and high resolution ratio of acoustic imaging. Due to low scattering properties of acoustic signal transmission in tissue, deeper penetration degree is obtained compared with a conventional optical imaging method. There is no need to slicing tissue and the method is non-invasive so that long-term monitoring is achieved. Photoacoustic microscope imaging equipment helps achieve imaging of multiple anatomical positions.

Compositions and methods for delivering a siRNA, dsRNA, or miRNA polynucleotide into a target cell comprising contacting the target cell with a mesenchymal stem cell, which mesenchymal stem cell comprises an exogenous DNA sequence expressing the siRNA or dsRNA polynucleotide, thereby delivering the siRNA, dsRNA, or miRNA polynucleotide to the target cell through a cellular protrusion or a microvesicle.

The present invention relates to the field of diagnostic imaging and provides compositions of ultrasound contrast agents, particularly gas-filled microvesicles suspensions, in combination with vital dyes. The compositions of the invention are advantageously used in the visualization of the lymphatic system, particularly for the detection of the sentinel lymph node or nodes of a tumor.

An apparatus for using ultrasonic microvesicle contrast medium to generate the thrombus of chosen blood capillary is composed of an ultrasonic microvesicle contrast medium generating injector, a region locating unit for determining the position where thrombus is needed, and an ultrasonic therapeutic unit.

The invention discloses an ultrasound super-resolution imaging method. The method comprises the following steps: firstly, emitting a time-space-frequency coding ultrasound radiography pulse sequence to an interested area into which ultrasound radiography microvesicle are injected;inhibiting a point spread function of a microvesicle backscattered signal; performing spatial diffraction attenuation transformation on a single-frame reconstructed radiography image of a receiving signal or centrally positioning the point spread function; converging the point spread function of a microvesicle signalin the image; and finally, performing time statistic analysis on a multi-frame converged image, enhancing a signal of a central position of the microvesicle, and inhibiting a background structure anda noise to form a super-resolution image. According to the ultrasound super-resolution imaging method disclosed by the invention, the phenomenon that a contradiction being difficult to reconcile exists between the positioning accuracy and the imaging speed of the microvesicle during ultrasound super-resolution blood flow imaging can be solved, and great improvement on the super-resolution imagingvelocity is realized.

The present invention relates to a new composition comprising gas-filled microvesicles for contrast imaging which are particularly suitable for providing an effective echo response to at least two selected ultrasound waves having different frequencies. Said composition preferably comprises at least two different preparations of gas-filled microvesicles, which preferably have respective different mean sizes. In particular, said preparations preferably have respective Dv values differing from each other by at least 0.5 μm, more preferably at least 1.0 μm. Alternatively, said composition has a volume size distribution showing a value of Bowley skewness of 0.16 or higher. According to a preferred embodiment, at least 95% of the total volume of gas contained in said microvesicles, calculated on the population of microvesicles up to a diameter of 10 μm, is contained in microvesicles having a diameter of 8 micron or less. The composition of the invention can be effectively employed at rather different ultrasound transmission frequencies differing by about 8 MHz.

The invention relates to a method for synthesizing p-hydroxybenzoic acid and esters by microvesicle bacteria. According to the invention, p-hydroxybenzoic acid is an organic synthetic raw material with wide usage for synthesizing liquid crystal, the esters have bacteriostatic activity and can be used as an antiseptic and widely used for preservation of food and cosmetics. The microvesicle bacteria for naturally synthesizing p-hydroxybenzoic acid and esters can be found in sea. Final accumulation concentration of p-hydroxybenzoic acid in a bacterial strain culture liquid is 10mM. The synthesized esters comprise methylparaben, ethyl ester, propyl ester, butyl ester, heptyl ester and pelargonic ester, each synthetic amount is about 2nM. For obtaining p-hydroxybenzoic acid, 2% of glucose is added in a sea culture medium for culturing A4B bacterial strain to a stable phase, hydrochloric acid is used for adjusting acidity, and ethyl acetate is used for extracting. Esters can be obtained by extracting the culture liquid under neutrallty condition. The industrial raw materials p-hydroxybenzoic acid and esters can be synthesized by microvesicle bacteria, and excessive dependence of petrifaction source by people can be reduced.

The invention discloses a dual tangential flow filtration system for exosome extraction and a preparation method and application of an exosome. The method comprises the following steps: putting a sample solution containing exosomes into a first storage tank, pumping the sample solution into a first filtering device, circularly concentrating and filtering, and collecting a filtrate into a second storage tank; when a volume of the liquid in the first storage tank is concentrated to the minimum operation volume, pumping the liquid in the second storage tank into a second filtering device, and carrying out circulating concentration and filtration; and collecting the liquid in the second storage tank to obtain the extracted and purified exosome solution. The exosome can be used for preparing exosome medical beauty products, exosome liquid dressings for promoting wound healing, exosome spray for relieving asthma and acute respiratory distress, and exosome related biological products. According to the invention, the exosome is extracted and purified through two tangential flow filtering membranes with different pore diameters, so that cell microvesicles and cell debris with larger particles in a sample can be removed, and the exosome can be extracted and concentrated to the greatest extent.

A method for detecting biomarkers of prostate cancer or other medical condition of the prostate based on the use of microvesicles obtained from urine samples, and the nucleic acids present in the microvesicles. The method disclosed herein are advantageous in that they may be used to support diagnosis, prognosis, monitoring, or therapy selection in lieu of or in conjunction with traditional biopsy-based diagnostics and do not require a digital rectal examination or prostate massage prior to urine sample collection.

The invention relates to the field of biomedicines, in particular to a magnetic acoustic contrast agent composition, a magnetic acoustic contrast agent, a magnetic microvesicle acoustic contrast agentand a preparation method of the magnetic acoustic contrast agent. The magnetic acoustic contrast agent composition comprises lipid, a surfactant and magnetic nanometer particles, wherein the surfactant consists of a surfactant A and a surfactant B; the surfactant A is in the free state, the surfactant B is in combined state to be modified on the surfaces of the magnetic nanometer particles; and the HLB value of the surfactant A is 8. Compared with the lipid of 1mol, the content of the surfactant A is 0.1-1mol, the content of the surfactant B is 0.1-1mol, and the content of the magnetic nanometer particles is 0.05-0.5mol. The magnetic microvesicle acoustic contrast agent prepared from the magnetic acoustic contrast agent composition has high stability, can meet in vivo circulation targeting delivery requirements, and realizes local high-concentration targeting delivery of medicines.

The invention provides inflatable nano microvesicle high-ash coal slime flotation equipment. The inflatable nano microvesicle high-ash coal slime flotation equipment comprises a main flotation columnand two secondary flotation columns, the main flotation column comprises an agent box, an ore pulp preprocessor, a high-speed disperser and a delivery pump which are mounted outside the main flotationcolumn, and an ore pulp multi-spot distributor mounted on the main flotation column, a foam collecting device, an atomizing spraying device, a bubble generator surrounding the outer wall of the lowerportion of the main flotation column, a conveying air pipe, an air storage tank and an air compressor are further included. The main flotation column and the secondary flotation columns are adopted for sequentially selecting concentrate, middlings and tailings are removed, and clean coal products with the ash content of 11% or below are finally obtained.

The invention provides a drug-loading polylactic acid microvesicle ultrasound contrast agent and a preparation method thereof, relating to a new preparation of antineoplastic drug. Specifically, the invention provides a drug-loading polylactic acid microvesicle ultrasound contrast agent with noticeable antineoplastic effect and a preparation method thereof. The drug-loading polylactic acid microvesicle ultrasound contrast agent comprises an adventitia material, a main drug and charge gas; wherein, the adventitia material is polylactic acid, the main drug is 10-hydroxycamptothecine and the charge gas is perfluoropropane; wherein, concentration of bulk main drug is 3-5mg / mL; the concentration of the adventitia material is 0.025-0.030g / mL. Under ultra audible sound, internal water phase containing hydroxycamptothecine is added to methylene dichloride containing polylactic acid to prepare initial emulsion; the initial emulsion is dispersed to external water phase containing polyvinyl alcohol by a membrane emulsifier to form diphase emulsion; low velocity stirring by magnetic force at constant temperature is carried out overnight to facilitate oil phase to volatize; the polylactic acid is solidified into envelope; microvesicle precipitation is collected and then is washed, cooled and dried; perfluoropropane is used to charge drug-loading microvesicle samples, thus obtaining the drug-loading microvesicle ultrasound contrast agent.

The invention relates to novel biomarker signature, diagnostic methods, kits and compositions for early diagnosis of ovarian cancer, based on microvesicles prepared from body fluid sample, specifically, uterine lavage fluid (UtLF) sample.

The invention belongs to the technical field of biology and particularly relates to a method for extracting extracellular vesicles of soft tissue and an application. The method comprises the steps ofobtaining an appropriate amount of target soft tissue from an organism, performing storage, performing culture, performing chromatography and the like. According to the method disclosed by the invention, extraction of exosomes or microvesicles of the soft tissue is simple, cell separation and purification processes are avoided, time and labor are saved and the cost is reduced. Furthermore, the physiological characteristics of in vivo soft tissue can be really reflected, the extracellular vesicles can be applied to disease diagnosis as effective physiological detection markers, and the defect in the exosomes or microvesicles of a body fluid or cell culture supernatant source is compensated.

The invention belongs to the technical field of liquid chromatographic separation, and particularly relates to a rapid and high-purity separation method of human plasma exosome. The method comprises the steps of firstly, removing apoptotic bodies and microvesicles of human plasma through high-speed centrifugation, then loading a sample to an agarose gel small column for pre-separation, and removing most of abundance proteins with relatively small sizes, such as human serum albumin and immune globulin; sequentially carrying out merging and ultrafiltration concentration on the collected fractions, and finally carrying out high performance liquid volume exclusion chromatography separation to realize separation of exosome and interference lipoprotein, thereby finally obtaining the high-purity human plasma exosome fraction. The whole process from plasma pretreatment to exosome fraction obtaining does not exceed two hours. Characterization of immunoblotting proves that the removal rate of high-density lipoprotein (HDL) can reach 95%, and the removal rate of low-density lipoprotein or very low-density lipoprotein (VHDL) can reach 85%.

A freeze-dried powder composition comprising a phospholipid and a polyethylene glycol, said polyethylene glycol having a percentage of folded polymeric chains higher than a predetermined limit. The composition is suitable for preparing gasfilled microvesicles.

A method of delivering exosomes and other micro vesicles to a biological target includes the steps of 1) providing blood, (2) separating plasma from the provided blood, and (3) separating the solution with the exosomes therefrom, (4) encapsulating the exosomes, and (5) delivering the exosomes. The step of encapsulation may be accomplished by water bead process, alginate bead process, spray drying bead formation, or plating. The biological target may be a human or animal heart, bone / joint, wound or skin. A method of encapsulating an exosome, a method of using an encapsulated exosome, compositions including encapsulated exosomes, and an encapsulated exosome per se are also disclosed.

The invention provides a phase change nano droplet regulation and control method based on a spatially heterogeneous focused eddy sound filed. The phase change nano droplet regulation and control method based on the spatially heterogeneous focused eddy sound filed comprises the steps that by adjusting relative power and a phase position among spherical focused ultrasonic transducer array elements,the heterogeneous focused eddy sound filed with symmetric distribution of sound pressure and a sound pressure maximum value existing on an annular antinode is generated, the heterogeneous focused eddysound filed is used for aggregating scattered phase change nano droplets to a micron-sized bulk droplet aggregate, so that a phase change threshold value of the phase change nano droplets is obviously reduced, a single microsecond short pulse is used for acting on the aggregated phase change nano droplets, then droplet phase change is induced, and the nano size distribution of the droplets in theaggregate ensures the vibration activity of phase change microvesicle. According to the phase change nano droplet regulation and control method based on the spatially heterogeneous focused eddy soundfiled, sound regulation and control of the phase change nano droplets under a living body condition has higher flexibility and safety.

The invention discloses a culture medium for producing alginate lyase by fermentation of a microvesicle bacterial genus. The culture medium comprises a strain culture medium and a fermentation culture medium. The invention further discloses a fermentation method for producing alginate lyase by the fermentation of microvesicle bacterial genus. According to the fermentation method, on the basis of shake flask fermentation, the screened microvesicle bacterial genus is subjected to fermentation culture with a fermentation tank, a research on fermentation condition optimization is conducted, and a lyase producing rule of the microvesicle bacterial genus in the fermentation tank is researched, so that the yield of alginate lyase is increased effectively; and alginate lyase produced by the fermentation of the microvesicle bacterial genus ALW1 is subjected to pilot scale amplification fermentation, so that important technical parameter guide is provided for future mass production.

The present invention relates to a new composition comprising gas-filled microvesicles for contrast imaging which are particularly suitable for providing an effective echo response to at least two selected ultrasound waves having different frequencies. Said composition preferably comprises at least two different preparations of gas-filled microvesicles having respective peaks of non-liner echographic response differing by at least 2 MHz to each other, and preferably have respective size distributions with different mean sizes. In particular, said preparations preferably have size distributions with respective DV50 values differing from each other by at least 0.5 μm, more preferably at least 1.0 μm. Alternatively, said composition has a volume size distribution showing a value of Bowley skewness of 0.16 or higher. According to a preferred embodiment, at least 95% of the total volume of gas contained in said microvesicles, calculated on the population of microvesicles up to a diameter of 10 μm, is contained in microvesicles having a diameter of 8 micron or less.

The invention discloses applications of gene modified mesenchymal stem cell derived microvesicles in preparation of drugs for treating renal injury. Applications of mesenchymal stem cell derived and gene modified miR-34a-MSC-MV, which are specifically designed microvesicles, in preparation of drugs for treating renal injury are included. The level of miR-34a is detected by inducing the overexpression of the miR-34a in MSCs through lentiviral vectors. Through the discovery from pathological observation, the damage level of renal tissue can be obviously improved, renal interstitial fibrosis, lymphocyte infiltration and swelling and necrosis degrees of renal tubules can be obviously alleviated, and renal histopathological scores can be significantly reduced. Through in vivo and in vitro experiments, repair effects of MV and miR-34a-MV are verified; the effects of gene modified stem cells and paracrine products thereof are cleared; and an action mechanism is preliminarily discussed.